.png){kind=icon}
.png){kind=icon}
Return
AI readiness for molecular precision medicine supply chains: evidence from Saudi Arabia
.png){kind=icon}
OA
AI
I
K
DOI：10.3389/fdgth.2026.1910051.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
IntroductionArtificial intelligence (AI) is reshaping molecular precision medicine through biomarker discovery; genomic variant interpretation; molecular imaging; multi-omics analysis; and patient-specific therapeutic support. In Saudi Arabia; genomic medicine and digital health initiatives are expanding; yet limited evidence explains how AI readiness supports molecular diagnostics; genomic testing; biobanking; biological sample traceability; and targeted therapy delivery.MethodsA structured cross-sectional survey was completed by 350 professionals from hospitals; molecular diagnostic laboratories; genomic testing centers; biomedical laboratories; biobanks; pharmaceutical and biologic suppliers; and healthcare service providers in Saudi Arabia. Data were analyzed using partial least squares structural equation modeling.ResultsAI readiness strengthened molecular data interoperability; biological sample traceability; diagnostic responsiveness; biomarker-guided decision support; and precision medicine service performance. Respondents from more AI-ready organizations reported stronger diagnostic responsiveness and fewer perceived workflow delays.DiscussionThe findings connect AI readiness with molecular diagnostics; genomic services; biomarker analytics; biobanking; and healthcare supply chain coordination; providing evidence to support AI-enabled molecular medicine transformation in Saudi Arabia.
Keywords:
biobanking
Saudi Arabia
molecular diagnostics
biomarker analysis
genomic testing
artificial intelligence readiness
biological sample traceability
healthcare supply chain
Journal
F
IF:
3.8
Papers:
2.0K
Citations:
3.1K
Organization
Cited Papers